Elanco Animal Health Inc (ELAN) stock
ELANNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 9/30111% above fair value
$23.06−0.18 (-0.77%)
Close on Oct 30, 2026Market cap $11.52BP/E –Yield –
Earnings
Elanco Animal Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 4, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$1.37B
+10.2% on a year earlier
Adjusted EPS, Q2 FY2026
$0.34
$0.26 a year earlier
Latest guidance
Raised
Aug 5, 2026 · 12 items
Quarterly results
Revenue and earnings per share from each of Elanco Animal Health's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026Expected | – | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026before the open | $1.37B | +10.2% | $0.11 | $0.34 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026before the open | $1.37B | +14.9% | $0.11 | $0.40 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 24, 2026before the open | $1.14B | +12.2% | -$0.56 | $0.13 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 5, 2025before the open | $1.14B | +10.4% | -$0.07 | $0.19 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025before the open | $1.24B | +4.8% | $0.02 | $0.26 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025before the open | $1.19B | -1.0% | $0.13 | $0.37 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 25, 2025before the open | $1.02B | -1.4% | -$0.02 | $0.14 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024before the open | $1.03B | -3.6% | $0.73 | $0.13 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | $1.18B | +12.0% | -$0.10 | $0.30 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024before the open | $1.21B | -4.1% | $0.06 | $0.34 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 26, 2024before the open | $1.04B | +4.8% | -$0.29 | $0.08 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023before the open | $1.07B | +3.9% | -$2.22 | $0.18 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 7, 2023before the open | $1.06B | -10.2% | -$0.20 | $0.18 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023before the open | $1.26B | +2.6% | $0.21 | $0.45 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 21, 2023before the open | $988.00M | -11.2% | -$0.11 | $0.19 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022before the open | $1.03B | -9.1% | -$0.10 | $0.20 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022before the open | $1.18B | – | -$0.04 | $0.36 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022before the open | $1.23B | – | $0.10 | $0.36 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022before the open | $1.11B | – | -$0.20 | $0.21 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 5, 2021before the open | $1.13B | – | -$0.21 | $0.19 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 9, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 7, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 24, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 6, 2020before the open | – | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Jul 30, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Elanco Animal Health's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Revenue | Q3 FY2026 | $1.20B – $1.22B | – | New | Aug 5, 2026 |
| revenue growthnon-GAAP | Q3 FY2026 | +5% – +7% | – | New | Aug 5, 2026 |
| Adjusted EBITDAnon-GAAP | Q3 FY2026 | $200.00M – $215.00M | – | New | Aug 5, 2026 |
| Adjusted Earnings per Sharenon-GAAP | Q3 FY2026 | $0.19 – $0.22 | – | New | Aug 5, 2026 |
| operating expensesnon-GAAP | Q3 FY2026 | +10% | – | New | Aug 5, 2026 |
| organic constant currency growthnon-GAAP | FY2026 | +6% – +7% | – | New | Aug 5, 2026 |
| organic constant currency revenue growth | FY2026 | +5% – +7% | – | New | May 6, 2026 |
| Revenue | FY2026 | $5.09B – $5.14B | $5.01B – $5.09B | Raised | Aug 5, 2026 |
| adjusted gross marginnon-GAAP | FY2026 | 55.2% – 55.6% | 55.1% – 55.5% | Raised | Aug 5, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $1.01B – $1.04B | $975.00M – $1.01B | Raised | Aug 5, 2026 |
| Adjusted EPSnon-GAAP | FY2026 | $1.10 – $1.16 | $1.03 – $1.09 | Raised | Aug 5, 2026 |
| innovation revenuenon-GAAP | FY2026 | $1.20B | – | New | May 6, 2026 |
| innovation revenue targetnon-GAAP | FY2026 | $1.25B | – | Raised | Aug 5, 2026 |
| year-end net leverage ratio targetnon-GAAP | FY2026 | 3 | 3 – 3.2 | Lowered | Aug 5, 2026 |
Guidance vs results
The last range Elanco Animal Health gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q2 FY2026 | Adjusted Earnings per Share | $0.25 – $0.28 | $0.34 | Above range |
| Q2 FY2026 | Revenue | $1.30B – $1.33B | $1.37B | Above range |
| Q1 FY2026 | Adjusted Earnings per Share | $0.33 – $0.36 | $0.40 | Above range |
| Q1 FY2026 | Revenue | $1.28B – $1.31B | $1.37B | Above range |
| FY2025 | Adjusted EPS | $0.91 – $0.94 | $0.95Σ4Q | Above range |
| FY2025 | EPS (GAAP) | -$0.11 – -$0.08 | -$0.48Σ4Q | Below range |
| FY2025 | Revenue | $4.65B – $4.67B | $4.72BΣ4Q | Above range |
| Q4 FY2025 | Adjusted Earnings per Share | $0.09 – $0.12 | $0.13 | Above range |
| Q4 FY2025 | EPS (GAAP) | -$0.20 – -$0.17 | -$0.56 | Below range |
| Q4 FY2025 | Revenue | $1.09B – $1.11B | $1.14B | Above range |
| Q3 FY2025 | Adjusted Earnings per Share | $0.12 – $0.16 | $0.19 | Above range |
| Q3 FY2025 | EPS (GAAP) | -$0.13 – -$0.09 | -$0.07 | Above range |
| Q3 FY2025 | Revenue | $1.08B – $1.11B | $1.14B | Above range |
| Q2 FY2025 | Adjusted Earnings per Share | $0.17 – $0.21 | $0.26 | Above range |
| Q2 FY2025 | EPS (GAAP) | -$0.04 – -$0.01 | $0.02 | Above range |
| Q2 FY2025 | Revenue | $1.18B – $1.20B | $1.24B | Above range |
| Q1 FY2025 | Adjusted earnings per share | $0.29 – $0.34 | $0.37 | Above range |
| Q1 FY2025 | EPS (GAAP) | $0.03 – $0.08 | $0.13 | Above range |
| Q1 FY2025 | Revenue | $1.16B – $1.18B | $1.19B | Above range |
| Q1 FY2025 | Revenue growth | +2% – +4% | -1% | Below range |
| Q4 FY2024 | Adjusted Earnings per Share | $0.13 – $0.18 | $0.14 | Within range |
| Q4 FY2024 | EPS (GAAP) | -$0.12 – -$0.06 | -$0.02 | Above range |
| Q4 FY2024 | Revenue | $1.00B – $1.03B | $1.02B | Within range |
| Q3 FY2024 | Adjusted Earnings per Share | $0.09 – $0.14 | $0.13 | Within range |
| Q3 FY2024 | EPS (GAAP) | $0.74 – $0.80 | $0.73 | Below range |
| Q3 FY2024 | Revenue | $1.02B – $1.05B | $1.03B | Within range |
| Q2 FY2024 | Adjusted Earnings per Share | $0.23 – $0.26 | $0.30 | Above range |
| Q2 FY2024 | EPS (GAAP) | $0.00 – $0.04 | -$0.10 | Below range |
| Q2 FY2024 | Revenue | $1.15B – $1.17B | $1.18B | Above range |
| Q1 FY2024 | Adjusted Earnings per Share | $0.25 – $0.28 | $0.34 | Above range |
| Q1 FY2024 | EPS (GAAP) | -$0.07 – -$0.03 | $0.06 | Above range |
| Q1 FY2024 | Revenue | $1.16B – $1.19B | $1.21B | Above range |
| Q4 FY2023 | Adjusted EPS | $0.07 – $0.13 | $0.08 | Within range |
| Q4 FY2023 | EPS (GAAP) | -$0.23 – -$0.17 | -$0.29 | Below range |
| Q4 FY2023 | Revenue | $978.00M – $1.02B | $1.04B | Above range |
| Q4 FY2023 | Revenue growth | +1% – +4% | +4.76% | Above range |
| Q3 FY2023 | Adjusted EPS | $0.08 – $0.13 | $0.18 | Above range |
| Q3 FY2023 | EPS (GAAP) | -$0.18 – -$0.14 | -$2.22 | Below range |
| Q3 FY2023 | Revenue | $1.03B – $1.06B | $1.07B | Above range |
| Q2 FY2023 | Adjusted EPS | $0.00 – $0.05 | $0.18 | Above range |
| Q2 FY2023 | EPS (GAAP) | -$0.31 – -$0.26 | -$0.20 | Above range |
| Q2 FY2023 | Revenue | $1.00B – $1.05B | $1.06B | Above range |
| Q4 FY2022 | Adjusted EPS | $0.10 – $0.16 | $0.19 | Above range |
| Q4 FY2022 | EPS (GAAP) | -$0.12 – -$0.07 | -$0.11 | Within range |
| Q4 FY2022 | Revenue | $955.00M – $1.00B | $988.00M | Within range |
| Q3 FY2022 | Adjusted EPS | $0.12 – $0.18 | $0.20 | Above range |
| Q3 FY2022 | EPS (GAAP) | -$0.12 – -$0.06 | -$0.10 | Within range |
| Q3 FY2022 | Revenue | $1.01B – $1.06B | $1.03B | Within range |
| Q2 FY2022 | diluted EPS | $0.22 – $0.28 | $0.36 | Above range |
| Q2 FY2022 | EPS (GAAP) | -$0.05 – $0.02 | -$0.04 | Within range |
| Q2 FY2022 | Revenue | $1.16B – $1.20B | $1.18B | Within range |
| Q1 FY2022 | adjusted basis | $0.33 – $0.38 | $0.36 | Within range |
| Q1 FY2022 | EPS (GAAP) | $0.01 – $0.07 | $0.10 | Above range |
| Q1 FY2022 | Revenue | $1.20B – $1.23B | $1.23B | Within range |
| Q4 FY2021 | adjusted basis | $0.13 – $0.19 | $0.21 | Above range |
| Q4 FY2021 | EPS (GAAP) | -$0.14 – -$0.07 | -$0.20 | Below range |
| Q4 FY2021 | Revenue | $1.08B – $1.12B | $1.11B | Within range |
Guidance history
Every forecast Elanco Animal Health put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 5, 2026 | Adjusted EBITDA | FY2026 | $1.01B – $1.04B | Raised |
| Aug 5, 2026 | Adjusted EBITDA | Q3 FY2026 | $200.00M – $215.00M | New |
| Aug 5, 2026 | Adjusted EPS | FY2026 | $1.10 – $1.16 | Raised |
| Aug 5, 2026 | Adjusted Earnings per Share | Q3 FY2026 | $0.19 – $0.22 | New |
| Aug 5, 2026 | adjusted gross margin | FY2026 | 55.2% – 55.6% | Raised |
| Aug 5, 2026 | year-end net leverage ratio target | FY2026 | 3 | Lowered |
| Aug 5, 2026 | innovation revenue target | FY2026 | $1.25B | Raised |
| Aug 5, 2026 | operating expenses | Q3 FY2026 | +10% | New |
| Aug 5, 2026 | organic constant currency growth | FY2026 | +6% – +7% | New |
| Aug 5, 2026 | Revenue | FY2026 | $5.09B – $5.14B | Raised |
| Aug 5, 2026 | revenue growth | Q3 FY2026 | +5% – +7% | New |
| Aug 5, 2026 | Revenue | Q3 FY2026 | $1.20B – $1.22B | New |
| May 6, 2026 | Adjusted EBITDA | FY2026 | $975.00M – $1.01B | Raised |
| May 6, 2026 | Adjusted EBITDA | Q2 FY2026 | $240.00M – $260.00M | New |
| May 6, 2026 | Adjusted Earnings per Share | FY2026 | $1.03 – $1.09 | Raised |
| May 6, 2026 | Adjusted Earnings per Share | Q2 FY2026 | $0.25 – $0.28 | New |
| May 6, 2026 | adjusted gross margin | FY2026 | 55.1% – 55.5% | New |
| May 6, 2026 | year-end net leverage ratio target | FY2026 | 3 – 3.2 | New |
| May 6, 2026 | innovation revenue | FY2026 | $1.20B | New |
| May 6, 2026 | operating expenses | Q2 FY2026 | +8% | New |
| May 6, 2026 | organic constant currency revenue growth | FY2026 | +5% – +7% | New |
| May 6, 2026 | Revenue | FY2026 | $5.01B – $5.09B | Raised |
| May 6, 2026 | organic constant currency revenue growth | Q2 FY2026 | +4% – +6% | New |
| May 6, 2026 | Revenue | Q2 FY2026 | $1.30B – $1.33B | New |
| Feb 24, 2026 | Adjusted EBITDA | FY2026 | $955.00M – $985.00M | New |
| Feb 24, 2026 | Adjusted EBITDA | Q1 FY2026 | $290.00M – $310.00M | New |
| Feb 24, 2026 | Adjusted EPS | FY2026 | $1.00 – $1.06 | New |
| Feb 24, 2026 | Adjusted Earnings per Share | Q1 FY2026 | $0.33 – $0.36 | New |
| Feb 24, 2026 | Revenue | FY2026 | $4.95B – $5.02B | New |
| Feb 24, 2026 | Revenue | Q1 FY2026 | $1.28B – $1.31B | New |
| Nov 5, 2025 | Adjusted EBITDA | FY2025 | $880.00M – $900.00M | New |
| Nov 5, 2025 | Adjusted EBITDA | Q4 FY2025 | $168.00M – $188.00M | New |
| Nov 5, 2025 | Adjusted EPS | FY2025 | $0.91 – $0.94 | New |
| Nov 5, 2025 | Adjusted Earnings per Share | Q4 FY2025 | $0.09 – $0.12 | New |
| Nov 5, 2025 | Reported Loss Per Share | FY2025 | -$0.11 – -$0.08 | New |
| Nov 5, 2025 | Reported Loss per Share | Q4 FY2025 | -$0.20 – -$0.17 | New |
| Nov 5, 2025 | adjusted gross margin | FY2025 | 54.9% – 55.2% | New |
| Nov 5, 2025 | Adjusted EBITDA margin | FY2025 | 18.9% – 19.3% | New |
| Nov 5, 2025 | operating expenses to increase | FY2025 | +8% | New |
| Nov 5, 2025 | innovation revenue target | FY2025 | $840.00M – $880.00M | New |
| Nov 5, 2025 | Reported Net Loss | FY2025 | -$56.00M – -$41.00M | New |
| Nov 5, 2025 | Adjusted EBITDA margin | Q4 FY2025 | 15.5% – 16.9% | New |
| Nov 5, 2025 | operating expenses up | Q4 FY2025 | +10% | New |
| Nov 5, 2025 | Reported Net Loss | Q4 FY2025 | -$100.00M – -$86.00M | New |
| Nov 5, 2025 | organic constant currency revenue growth | FY2025 | +6% – +6.5% | New |
| Nov 5, 2025 | revenue | FY2025 | $4.65B – $4.67B | New |
| Nov 5, 2025 | organic constant currency revenue growth | Q4 FY2025 | +4% – +6% | New |
| Nov 5, 2025 | Revenue | Q4 FY2025 | $1.09B – $1.11B | New |
| Aug 7, 2025 | Adjusted EBITDA | Q3 FY2025 | $160.00M – $180.00M | New |
| Aug 7, 2025 | Adjusted EBITDA | FY2025 | $850.00M – $890.00M | Raised |
| Aug 7, 2025 | Adjusted Earnings per Share | Q3 FY2025 | $0.12 – $0.16 | New |
| Aug 7, 2025 | Adjusted EPS | FY2025 | $0.85 – $0.91 | Raised |
| Aug 7, 2025 | Reported Loss per Share | Q3 FY2025 | -$0.13 – -$0.09 | New |
| Aug 7, 2025 | Reported Loss Per Share | FY2025 | -$0.08 – -$0.03 | Lowered |
| Aug 7, 2025 | adjusted gross margin | FY2025 | 54.5% – 55% | Raised |
| Aug 7, 2025 | Adjusted EBITDA margin | Q3 FY2025 | 14.8% – 16.2% | New |
| Aug 7, 2025 | operating expenses up in constant currency | Q3 FY2025 | +8% | New |
| Aug 7, 2025 | Reported Net Loss | Q3 FY2025 | -$66.00M – -$45.00M | New |
| Aug 7, 2025 | year-end net leverage ratio target | FY2025 | 3.8 – 4.1 | New |
| Aug 7, 2025 | Adjusted EBITDA margin | FY2025 | 18.6% – 19.3% | Lowered |
| Aug 7, 2025 | operating expenses increase in constant currency | FY2025 | +7% | New |
| Aug 7, 2025 | gross debt paydown | FY2025 | $500.00M – $550.00M | New |
| Aug 7, 2025 | Reported Net Loss | FY2025 | -$38.00M – -$14.00M | New |
| Aug 7, 2025 | organic constant currency revenue growth | Q3 FY2025 | +4% – +6% | New |
| Aug 7, 2025 | Revenue | Q3 FY2025 | $1.08B – $1.11B | New |
| Aug 7, 2025 | organic constant currency revenue growth | FY2025 | +5% – +6% | New |
| Aug 7, 2025 | Revenue | FY2025 | $4.57B – $4.62B | Raised |
| Aug 7, 2025 | innovation revenue target | FY2025 | $720.00M – $800.00M | Lowered |
| May 7, 2025 | Adjusted EBITDA | Q2 FY2025 | $200.00M – $220.00M | New |
| May 7, 2025 | Adjusted EBITDA | FY2025 | $830.00M – $870.00M | Reaffirmed |
| May 7, 2025 | Adjusted Earnings per Share | Q2 FY2025 | $0.17 – $0.21 | New |
| May 7, 2025 | Adjusted EPS | FY2025 | $0.80 – $0.86 | Reaffirmed |
| May 7, 2025 | Reported Loss per Share | Q2 FY2025 | -$0.04 – -$0.01 | New |
| May 7, 2025 | Reported Loss Per Share | FY2025 | -$0.07 – -$0.01 | Lowered |
| May 7, 2025 | adjusted gross margin | FY2025 | 54.2% – 54.7% | New |
| May 7, 2025 | organic constant currency revenue growth | Q2 FY2025 | +4% – +6% | New |
| May 7, 2025 | Revenue | Q2 FY2025 | $1.18B – $1.20B | New |
| May 7, 2025 | revenue | FY2025 | $4.51B – $4.58B | Raised |
| May 7, 2025 | innovation revenue target | FY2025 | $660.00M – $740.00M | Lowered |
| Feb 25, 2025 | Adjusted EBITDA | Q1 FY2025 | $240.00M – $260.00M | New |
| Feb 25, 2025 | Adjusted EBITDA | FY2025 | $830.00M – $870.00M | New |
| Feb 25, 2025 | Adjusted earnings per share | Q1 FY2025 | $0.29 – $0.34 | New |
| Feb 25, 2025 | Adjusted earnings per share | FY2025 | $0.80 – $0.86 | New |
| Feb 25, 2025 | Reported income per share | Q1 FY2025 | $0.03 – $0.08 | New |
| Feb 25, 2025 | Reported (Loss) Income per Share | FY2025 | -$0.05 – $0.01 | New |
| Feb 25, 2025 | Adjusted EBITDA margin | Q1 FY2025 | 21% – 22.2% | New |
| Feb 25, 2025 | Adjusted EBITDA margin | FY2025 | 18.7% – 19.3% | New |
| Feb 25, 2025 | tax rate | FY2025 | 21% – 22% | New |
| Feb 25, 2025 | revenue growth | Q1 FY2025 | +2% – +4% | New |
| Feb 25, 2025 | Revenue | Q1 FY2025 | $1.16B – $1.18B | New |
| Feb 25, 2025 | innovation revenue target | FY2025 | $640.00M – $720.00M | New |
| Feb 25, 2025 | Revenue | FY2025 | $4.45B – $4.51B | Raised |
| Nov 7, 2024 | Adjusted EBITDA | Q4 FY2024 | $167.00M – $197.00M | New |
| Nov 7, 2024 | Adjusted EBITDA | FY2024 | $900.00M – $930.00M | Lowered |
| Nov 7, 2024 | Adjusted Earnings per Share | Q4 FY2024 | $0.13 – $0.18 | New |
| Nov 7, 2024 | Adjusted EPS | FY2024 | $0.89 – $0.95 | Narrowed |
| Nov 7, 2024 | Reported Loss per Share | Q4 FY2024 | -$0.12 – -$0.06 | New |
| Nov 7, 2024 | Reported EPS | FY2024 | $0.58 – $0.64 | Lowered |
| Nov 7, 2024 | Adjusted EBITDA margin | Q4 FY2024 | 16.7% – 19.1% | New |
| Nov 7, 2024 | Adjusted EBITDA margin | FY2024 | 20.4% – 20.9% | New |
| Nov 7, 2024 | Reported Net Loss | Q4 FY2024 | -$59.00M – -$32.00M | New |
| Nov 7, 2024 | Reported Net Income | FY2024 | $286.00M – $317.00M | Lowered |
| Nov 7, 2024 | organic constant currency revenue growth | Q4 FY2024 | +1% – +4% | New |
| Nov 7, 2024 | Revenue | Q4 FY2024 | $1.00B – $1.03B | New |
| Nov 7, 2024 | organic constant currency growth | FY2024 | +3% | Lowered |
| Nov 7, 2024 | Revenue | FY2024 | $4.42B – $4.45B | Narrowed |
| Nov 7, 2024 | innovation sales contribution | FY2024 | $420.00M – $450.00M | New |
| Nov 7, 2024 | innovation sales | FY2025 | $600.00M – $700.00M | New |
| Aug 8, 2024 | Adjusted EBITDA | Q3 FY2024 | $140.00M – $170.00M | New |
| Aug 8, 2024 | adjusted EBITDA | FY2024 | $900.00M – $940.00M | Lowered |
| Aug 8, 2024 | Adjusted Earnings per Share | Q3 FY2024 | $0.09 – $0.14 | New |
| Aug 8, 2024 | adjusted EPS | FY2024 | $0.88 – $0.96 | Reaffirmed |
| Aug 8, 2024 | Reported Earnings per Share | Q3 FY2024 | $0.74 – $0.80 | New |
| Aug 8, 2024 | Reported EPS | FY2024 | $0.63 – $0.71 | Raised |
| Aug 8, 2024 | Adjusted EBITDA margin | Q3 FY2024 | 13.7% – 16.2% | New |
| Aug 8, 2024 | Reported Net Income | Q3 FY2024 | $368.00M – $396.00M | New |
| Aug 8, 2024 | Adjusted EBITDA margin | FY2024 | 20.4% – 21.1% | Lowered |
| Aug 8, 2024 | Reported Net Income | FY2024 | $314.00M – $352.00M | Raised |
| Aug 8, 2024 | organic constant currency revenue growth | Q3 FY2024 | +1% – +3% | New |
| Aug 8, 2024 | revenue | Q3 FY2024 | $1.02B – $1.05B | New |
| Aug 8, 2024 | organic constant currency revenue growth | FY2024 | +3% – +4% | Raised |
| Aug 8, 2024 | revenue | FY2024 | $4.41B – $4.46B | Lowered |
| May 8, 2024 | Adjusted EBITDA | Q2 FY2024 | $240.00M – $260.00M | New |
| May 8, 2024 | Adjusted EBITDA | FY2024 | $960.00M – $1.00B | Lowered |
| May 8, 2024 | Adjusted Earnings per Share | Q2 FY2024 | $0.23 – $0.26 | New |
| May 8, 2024 | Adjusted EPS | FY2024 | $0.88 – $0.96 | Raised |
| May 8, 2024 | Reported Earnings per Share | Q2 FY2024 | $0.00 – $0.04 | New |
| May 8, 2024 | Reported EPS | FY2024 | -$0.09 – -$0.01 | Raised |
| May 8, 2024 | Adjusted EBITDA margin | Q2 FY2024 | 21% – 22.2% | New |
| May 8, 2024 | Reported Net Income | Q2 FY2024 | $0 – $20.00M | New |
| May 8, 2024 | Adjusted EBITDA margin | FY2024 | 21.5% – 22.1% | New |
| May 8, 2024 | Reported Net Loss | FY2024 | -$45.00M – -$3.00M | New |
| May 8, 2024 | constant currency revenue growth | Q2 FY2024 | +1% – +3% | New |
| May 8, 2024 | Revenue | Q2 FY2024 | $1.15B – $1.17B | New |
| May 8, 2024 | constant currency revenue growth | FY2024 | +2% – +3% | New |
| May 8, 2024 | Revenue | FY2024 | $4.46B – $4.52B | New |
| Feb 26, 2024 | Adjusted EBITDA | FY2024 | $960.00M – $1.01B | New |
| Feb 26, 2024 | Adjusted EBITDA | Q1 FY2024 | $255.00M – $275.00M | New |
| Feb 26, 2024 | Adjusted Earnings per Share | Q1 FY2024 | $0.25 – $0.28 | New |
| Feb 26, 2024 | Adjusted EPS | FY2024 | $0.87 – $0.95 | New |
| Feb 26, 2024 | Reported Loss per Share | Q1 FY2024 | -$0.07 – -$0.03 | New |
| Feb 26, 2024 | Reported EPS | FY2024 | -$0.12 – -$0.03 | New |
| Feb 26, 2024 | Revenue | Q1 FY2024 | $1.16B – $1.19B | New |
| Feb 26, 2024 | Revenue | FY2024 | $4.45B – $4.54B | New |
| Nov 7, 2023 | Adjusted EBITDA | Q4 FY2023 | $151.00M – $186.00M | New |
| Nov 7, 2023 | Adjusted EBITDA | FY2023 | $965.00M – $1.00B | Narrowed |
| Nov 7, 2023 | Adjusted EPS | FY2023 | $0.88 – $0.94 | Raised |
| Nov 7, 2023 | Adjusted EPS | Q4 FY2023 | $0.07 – $0.13 | New |
| Nov 7, 2023 | Reported diluted EPS | FY2023 | -$2.43 – -$2.37 | Lowered |
| Nov 7, 2023 | Reported EPS | Q4 FY2023 | -$0.23 – -$0.17 | New |
| Nov 7, 2023 | Revenue | Q4 FY2023 | $978.00M – $1.02B | New |
| Nov 7, 2023 | revenue growth | Q4 FY2023 | +1% – +4% | New |
| Nov 7, 2023 | Revenue | FY2023 | $4.36B – $4.40B | Narrowed |
| Aug 7, 2023 | Adjusted EBITDA | Q3 FY2023 | $170.00M – $200.00M | New |
| Aug 7, 2023 | Adjusted EBITDA | FY2023 | $950.00M – $1.01B | Raised |
| Aug 7, 2023 | Adjusted EPS | Q3 FY2023 | $0.08 – $0.13 | New |
| Aug 7, 2023 | Adjusted EPS | FY2023 | $0.80 – $0.89 | Raised |
| Aug 7, 2023 | Reported EPS | Q3 FY2023 | -$0.18 – -$0.14 | New |
| Aug 7, 2023 | Reported diluted EPS | FY2023 | -$0.34 – -$0.26 | Lowered |
| Aug 7, 2023 | Revenue | Q3 FY2023 | $1.03B – $1.06B | New |
| Aug 7, 2023 | Revenue | FY2023 | $4.35B – $4.41B | Raised |
| May 9, 2023 | Adjusted EBITDA | Q2 FY2023 | $131.00M – $161.00M | New |
| May 9, 2023 | Adjusted EBITDA | FY2023 | $940.00M – $1.00B | Raised |
| May 9, 2023 | Adjusted EPS | Q2 FY2023 | $0.00 – $0.05 | New |
| May 9, 2023 | Adjusted EPS | FY2023 | $0.76 – $0.83 | Raised |
| May 9, 2023 | Reported EPS | Q2 FY2023 | -$0.31 – -$0.26 | New |
| May 9, 2023 | Reported diluted EPS | FY2023 | -$0.27 – -$0.20 | Lowered |
| May 9, 2023 | Revenue | Q2 FY2023 | $1.00B – $1.05B | New |
| May 9, 2023 | Revenue | FY2023 | $4.31B – $4.40B | New |
| Feb 21, 2023 | Adjusted EBITDA | FY2023 | $920.00M – $1.00B | New |
| Feb 21, 2023 | Adjusted EBITDA | FY2023 | $490.00M – $540.00M | Lowered |
| Feb 21, 2023 | Adjusted EPS | FY2023 | $0.74 – $0.83 | New |
| Feb 21, 2023 | Adjusted Earnings per Share | FY2023 | $0.43 – $0.50 | Lowered |
| Feb 21, 2023 | Reported EPS | FY2023 | -$0.32 – -$0.22 | New |
| Feb 21, 2023 | Reported Loss per Share | FY2023 | -$0.11 – -$0.04 | Raised |
| Feb 21, 2023 | Reported Net Loss | FY2023 | -$157.00M – -$109.00M | New |
| Feb 21, 2023 | Reported Net Loss | FY2023 | -$53.00M – -$22.00M | Raised |
| Feb 21, 2023 | Revenue | FY2023 | $4.28B – $4.40B | New |
| Feb 21, 2023 | Revenue | FY2023 | $2.23B – $2.31B | Lowered |
| Nov 8, 2022 | Adjusted EBITDA | Q4 FY2022 | $165.00M – $200.00M | New |
| Nov 8, 2022 | Adjusted EBITDA | FY2022 | $1.01B – $1.05B | Lowered |
| Nov 8, 2022 | Adjusted EPS | Q4 FY2022 | $0.10 – $0.16 | New |
| Nov 8, 2022 | Adjusted EPS | FY2022 | $1.01 – $1.07 | Lowered |
| Nov 8, 2022 | Reported EPS | Q4 FY2022 | -$0.12 – -$0.07 | New |
| Nov 8, 2022 | Reported diluted EPS | FY2022 | -$0.17 – -$0.12 | Lowered |
| Nov 8, 2022 | Reported Net Income (Loss) | Q4 FY2022 | -$59.00M – -$34.00M | New |
| Nov 8, 2022 | Reported Net Loss | FY2022 | -$82.00M – -$57.00M | Lowered |
| Nov 8, 2022 | Revenue | Q4 FY2022 | $955.00M – $1.00B | New |
| Nov 8, 2022 | Revenue | FY2022 | $4.39B – $4.43B | Lowered |
| Aug 8, 2022 | Adjusted EBITDA | Q3 FY2022 | $175.00M – $215.00M | New |
| Aug 8, 2022 | Adjusted EBITDA | FY2022 | $1.06B – $1.10B | Lowered |
| Aug 8, 2022 | Adjusted EPS | Q3 FY2022 | $0.12 – $0.18 | New |
| Aug 8, 2022 | Adjusted EPS | FY2022 | $1.06 – $1.13 | Lowered |
| Aug 8, 2022 | Reported diluted EPS | Q3 FY2022 | -$0.12 – -$0.06 | New |
| Aug 8, 2022 | Reported diluted EPS | FY2022 | -$0.10 – -$0.03 | Lowered |
| Aug 8, 2022 | Adjusted EBITDA margin | Q3 FY2022 | 17.3% – 20.3% | New |
| Aug 8, 2022 | Reported Net Loss | Q3 FY2022 | -$61.00M – -$32.00M | New |
| Aug 8, 2022 | Net leverage ratio | FY2022 | 5 | New |
| Aug 8, 2022 | Adjusted EBITDA margin | FY2022 | 23.7% – 24.2% | Lowered |
| Aug 8, 2022 | Reported Net Loss | FY2022 | -$48.00M – -$15.00M | Lowered |
| Aug 8, 2022 | Revenue | Q3 FY2022 | $1.01B – $1.06B | New |
| Aug 8, 2022 | Revenue | FY2022 | $4.47B – $4.55B | Lowered |
| May 9, 2022 | Adjusted EBITDA | Q2 FY2022 | $245.00M – $275.00M | New |
| May 9, 2022 | Adjusted EBITDA | FY2022 | $1.13B – $1.17B | Lowered |
| May 9, 2022 | diluted EPS | Q2 FY2022 | $0.22 – $0.28 | New |
| May 9, 2022 | diluted EPS | FY2022 | $1.15 – $1.21 | Lowered |
| May 9, 2022 | diluted EPS | Q2 FY2022 | -$0.05 – $0.02 | New |
| May 9, 2022 | diluted EPS | FY2022 | $0.02 – $0.09 | Raised |
| May 9, 2022 | Adjusted EBITDA margin | Q2 FY2022 | 21% – 23% | New |
| May 9, 2022 | Reported net income (loss) | Q2 FY2022 | -$23.00M – $6.00M | New |
| May 9, 2022 | Adjusted EBITDA margin | FY2022 | 24% – 25% | New |
| May 9, 2022 | Reported net income | FY2022 | $10.00M – $41.00M | Raised |
| May 9, 2022 | revenue | Q2 FY2022 | $1.16B – $1.20B | New |
| May 9, 2022 | revenue | FY2022 | $4.70B – $4.76B | Lowered |
| Feb 24, 2022 | Adjusted EBITDA | Q1 FY2022 | $310.00M – $340.00M | New |
| Feb 24, 2022 | Adjusted EBITDA | FY2022 | $1.14B – $1.18B | New |
| Feb 24, 2022 | adjusted basis | Q1 FY2022 | $0.33 – $0.38 | New |
| Feb 24, 2022 | diluted EPS on an adjusted basis | FY2022 | $1.18 – $1.24 | New |
| Feb 24, 2022 | diluted EPS on a reported basis | Q1 FY2022 | $0.01 – $0.07 | New |
| Feb 24, 2022 | diluted EPS on a reported basis | FY2022 | $0.01 – $0.07 | New |
| Feb 24, 2022 | Reported Net Income | Q1 FY2022 | $7.00M – $33.00M | New |
| Feb 24, 2022 | Reported Net Income | FY2022 | $4.00M – $27.00M | New |
| Feb 24, 2022 | revenue | Q1 FY2022 | $1.20B – $1.23B | New |
| Feb 24, 2022 | growth on a constant currency basis | FY2022 | +2% – +3% | New |
| Feb 24, 2022 | revenue | FY2022 | $4.75B – $4.80B | New |
| Nov 5, 2021 | adjusted EBITDA | Q4 FY2021 | $190.00M – $230.00M | New |
| Nov 5, 2021 | adjusted EBITDA | FY2021 | $1.04B – $1.08B | New |
| Nov 5, 2021 | adjusted basis | Q4 FY2021 | $0.13 – $0.19 | New |
| Nov 5, 2021 | adjusted EPS | FY2021 | $0.97 – $1.03 | New |
| Nov 5, 2021 | diluted EPS | Q4 FY2021 | -$0.14 – -$0.07 | New |
| Nov 5, 2021 | diluted EPS | FY2021 | -$0.91 – -$0.83 | New |
| Nov 5, 2021 | reported net loss | Q4 FY2021 | -$65.00M – -$30.00M | New |
| Nov 5, 2021 | reported net loss | FY2021 | -$405.00M – -$360.00M | New |
| Nov 5, 2021 | revenue | Q4 FY2021 | $1.08B – $1.12B | New |
| Nov 5, 2021 | revenue | FY2021 | $4.73B – $4.77B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Elanco Animal Health filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Update
- Results
- Results
- Update
- Results
- Update
- Results
- Update
- Update
- Results
- Results